Literature DB >> 18615704

Sensitive periods for developmental toxicity of orally administered artesunate in the rat.

Tacey E K White1, Robert L Clark.   

Abstract

BACKGROUND: Artesunate has been reported to cause embryolethality and malformations when administered orally to rats during organogenesis. The purpose of this study was to determine the most sensitive period(s) for the induction of these effects in order to provide clues about possible mechanisms and to identify a short treatment regimen for further studies.
METHODS: Pregnant rats were orally administered artesunate (10, 17 or 30 mg/kg/day) on single or multiple days of gestation. Cesarean sections and fetal evaluations were conducted on Day 21 postcoitum (pc).
RESULTS: Embryolethality, cardiovascular malformations and a syndrome of skeletal defects were observed after single doses on days 10 to 14 pc, while no developmental effects were observed before (day 9 pc) or after (days 16 or 17 pc) that period. The most sensitive day for embryo lethality was day 11 pc, where lethality occurred with a very steep dose response (postimplantation loss was approximately 15% at 10 mg/kg and 100% at 17 mg/kg/day). The most sensitive day for the induction of malformations was day 10 pc. Malformations tended to occur in partially resorbed litters and included cardiovascular defects and bent and misshapen long bones and scapulae.
CONCLUSIONS: The sensitive window for developmental toxicity of artesunate in the rat was identified as days 10 to 14 pc. Single oral doses produced embryolethality and similar cardiovascular and skeletal malformations as previously reported in longer term dosing experiments. These single dose treatment regimens could be useful to further investigate the mechanistic basis for artesunate-induced developmental toxicity. Copyright 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18615704     DOI: 10.1002/bdrb.20157

Source DB:  PubMed          Journal:  Birth Defects Res B Dev Reprod Toxicol        ISSN: 1542-9733


  15 in total

Review 1.  A systematic review of the safety and efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria during pregnancy.

Authors:  Christine Manyando; Kassoum Kayentao; Umberto D'Alessandro; Henrietta U Okafor; Elizabeth Juma; Kamal Hamed
Journal:  Malar J       Date:  2012-05-01       Impact factor: 2.979

2.  Patterns of anti-malarial drug treatment among pregnant women in Uganda.

Authors:  Laura R Sangaré; Noel S Weiss; Paula E Brentlinger; Barbra A Richardson; Sarah G Staedke; Mpungu S Kiwuwa; Andy Stergachis
Journal:  Malar J       Date:  2011-06-06       Impact factor: 2.979

3.  Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study.

Authors:  R McGready; S J Lee; J Wiladphaingern; E A Ashley; M J Rijken; M Boel; J A Simpson; M K Paw; M Pimanpanarak; Oh Mu; P Singhasivanon; N J White; F H Nosten
Journal:  Lancet Infect Dis       Date:  2011-12-12       Impact factor: 25.071

4.  Exposure to artemether-lumefantrine (Coartem) in first trimester pregnancy in an observational study in Zambia.

Authors:  Christine Manyando; Eric M Njunju; Mailis Virtanen; Kamal Hamed; Melba Gomes; Jean-Pierre Van Geertruyden
Journal:  Malar J       Date:  2015-02-14       Impact factor: 2.979

5.  Safety of artemisinins in first trimester of prospectively followed pregnancies: an observational study.

Authors:  Kerryn A Moore; Julie A Simpson; Moo Kho Paw; MuPawJay Pimanpanarak; Jacher Wiladphaingern; Marcus J Rijken; Podjanee Jittamala; Nicholas J White; Freya J I Fowkes; François Nosten; Rose McGready
Journal:  Lancet Infect Dis       Date:  2016-02-08       Impact factor: 25.071

Review 6.  Systematic literature review and meta-analysis of the efficacy of artemisinin-based and quinine-based treatments for uncomplicated falciparum malaria in pregnancy: methodological challenges.

Authors:  Makoto Saito; Mary Ellen Gilder; François Nosten; Rose McGready; Philippe J Guérin
Journal:  Malar J       Date:  2017-12-13       Impact factor: 2.979

Review 7.  Pregnancy exposure registries for assessing antimalarial drug safety in pregnancy in malaria-endemic countries.

Authors:  Stephanie Dellicour; Feiko O ter Kuile; Andy Stergachis
Journal:  PLoS Med       Date:  2008-09-09       Impact factor: 11.069

8.  Safety of artemether-lumefantrine exposure in first trimester of pregnancy: an observational cohort.

Authors:  Dominic Mosha; Festo Mazuguni; Sigilbert Mrema; Esperanca Sevene; Salim Abdulla; Blaise Genton
Journal:  Malar J       Date:  2014-05-27       Impact factor: 2.979

9.  Risks of miscarriage and inadvertent exposure to artemisinin derivatives in the first trimester of pregnancy: a prospective cohort study in western Kenya.

Authors:  Stephanie Dellicour; Meghna Desai; George Aol; Martina Oneko; Peter Ouma; Godfrey Bigogo; Deron C Burton; Robert F Breiman; Mary J Hamel; Laurence Slutsker; Daniel Feikin; Simon Kariuki; Frank Odhiambo; Jayesh Pandit; Kayla F Laserson; Greg Calip; Andy Stergachis; Feiko O ter Kuile
Journal:  Malar J       Date:  2015-11-18       Impact factor: 2.979

10.  Assessment of the safety of antimalarial drug use during early pregnancy (ASAP): protocol for a multicenter prospective cohort study in Burkina Faso, Kenya and Mozambique.

Authors:  Halidou Tinto; Esperança Sevene; Stephanie Dellicour; Gregory S Calip; Umberto d'Alessandro; Eusébio Macete; Seydou Nakanabo-Diallo; Adama Kazienga; Innocent Valea; Hermann Sorgho; Anifa Valá; Orvalho Augusto; Maria Ruperez; Clara Menendez; Peter Ouma; Meghna Desai; Feiko Ter Kuile; Andy Stergachis
Journal:  Reprod Health       Date:  2015-12-04       Impact factor: 3.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.